Dickran Kazandjian, MD¹, Elizabeth Hill, MD², Candis Morrison, CNP, PhD^2*, Alexander Dew, DO, MS³, Neha Korde, MD⁴, Sham Mailankody, MBBS⁴, Elisabet E. Manasanch, MD⁵, Mary L. Kwok, MD⁶, Manisha Bhutani, MD⁷, Nishant Tageja, MD⁸, Yong Zhang, Ph.D.^9*, Ashley Carpenter, RN^2*, Monica Epstein, RN^2*, Michael Emanuel, BSN, RN^10*, Crystal Lu, PharmD, BCOP^11*, Raul C. Braylan, MD¹², Katherine R. Calvo, MD, PhD¹², Peter Choyke, MD^13*, Alina Dulau-Florea, MD^14*, Esther Mena, MD^13*, Liza Lindenberg, MD^13*, Irina Maric, MD, MSci¹⁵, Nisha Patel, DO^16*, Maryalice Stetler-Stevenson, MD, PhD^17*, Hao-Wei Wang, MD, PhD¹⁸, Constance M. Yuan, MD, PhD^17*, Seth M. Steinberg, PhD^19*, William D. Figg, PhD^20*, Mark Roschewski, MD²¹ and Ola Landgren, MD, PhD⁴

¹Center for Cancer Research, Lymphoid Malignancies Branch, Multiple Myeloma Program, NIH, Potomac, MD
²Center for Cancer Research, Lymphoid Malignancies Branch, Multiple Myeloma Program, National Cancer Institute, National Institutes of Health, Bethesda, MD
³Walter Reed Medical Center, North Bethesda, MD
⁴Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Walter Reed National Military Medical Ctr., Bethesda, MD
⁷Levine L. Cancer Institute, Charlotte, NC
⁸Wheeling Hospital, Monroeville, PA
⁹National Cancer Institute, National Institutes of Health, Center for Cancer Research, Bethesda, MD
¹⁰Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
¹¹Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD
¹²Hematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
¹³Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
¹⁴National Institutes of Health Clinical Center, Bethesda, MD
¹⁵Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
¹⁶National Institutes of Health, Bethesda, MD
¹⁷Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD
¹⁸Department of Laboratory Medicine, National Cancer Institute, National Institute of Health, Bethesda, MD
¹⁹Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD
²⁰Molecular Pharmacology Section, Genitourinary Malignancies Section, National Cancer Institute, Bethesda, MD
²¹Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Jonathan L. Kaufman, MD¹, Jacob P. Laubach^2*, Douglas Sborov, MD, MS³, Brandi Reeves, MD⁴, Cesar Rodriguez, MD⁵, Ajai Chari^6*, Rebecca W. Silbermann, MD⁷, Luciano J. Costa, MD, PhD⁸, Larry D. Anderson Jr., MD, PhD⁹, Nitya Nathwani, MD¹⁰, Nina Shah, MD¹¹, Yvonne A. Efebera, MD, MPH¹², Sarah A. Holstein, MD, PhD¹³, Caitlin Costello^14*, Andrzej Jakubowiak, MD, PhD¹⁵, Tanya M. Wildes, MD, MSc¹⁶, Robert Z. Orlowski, MD, PhD¹⁷, Kenneth H. Shain, MD, PhD ¹⁸, Andrew J. Cowan^19*, Yana Lutska, PharmD^20*, Padma Bobba^20*, Huiling Pei, PhD^21*, Jon Ukropec, PhD²², Jessica Vermeulen, MD, PhD²³, Thomas S. Lin, MD, PhD²⁰, Paul G. Richardson, MD² and Peter M. Voorhees^24*

¹Winship Cancer Institute, Emory University, Atlanta, GA
²Dana-Farber Cancer Institute, Boston, MA
³Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
⁴University of North Carolina-Chapel Hill, Chapel Hill, NC
⁵Wake Forest University School of Medicine, Winston-Salem, NC
⁶Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
⁷Knight Cancer Institute, Oregon Health and Science University, Portland, OR
⁸University of Alabama at Birmingham, Birmingham, AL
⁹Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
¹⁰Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA
¹¹Department of Medicine, University of California San Francisco, San Francisco, CA
¹²The Ohio State University Comprehensive Cancer Center, Columbus, OH
¹³Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE
¹⁴Moores Cancer Center, University of California San Diego, La Jolla, CA
¹⁵University of Chicago Medical Center, Chicago, IL
¹⁶Division of Oncology, Section Medical Oncology, Washington University School of Medicine, St. Louis, MO
¹⁷Department of Lymphoma–Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
¹⁸Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
¹⁹Division of Medical Oncology, University of Washington, Seattle, WA
²⁰Janssen Scientific Affairs, LLC, Horsham, PA
²¹Janssen Research & Development, LLC, Titusville, NJ
²²Janssen Global Medical Affairs, Horsham, PA
²³Janssen Research & Development, LLC, Leiden, Netherlands
²⁴Levine Cancer Institute, Atrium Health, Charlotte, NC

Pieter Sonneveld, MD, PhD¹, Meral Beksac, MD², Bronno Van Der Holt, PhD^3*, Meletios A Dimopoulos⁴, Angelo Michele Carella, MD^5*, Heinz Ludwig, MD⁶, Sonja Zweegman, MD, PhD⁷, Thilo Zander, MD^8*, Ruth Wester, MD^1*, Roman Hajek, MD⁹, Lucia Pantani, MD, PhD^10*, Luca Dozza, MSc^10*, Francesca Gay, MD¹¹, Anna Maria Cafro^12*, Luca De Rosa^13*, Francesca Fioritoni, MD^14*, Ulf-Henrik Mellqvist, MD, PhD¹⁵, Rossella Troia, PharmD^16*, Niels Frost Andersen, MD, PhD^17*, Ka Lung Wu, MD, PhD¹⁸, Christoph Driessen, MD¹⁹, Susana Carvalho, MD^20*, Alexandra J. Croockewit, MD, PhD^21*, Fredrik Schjesvold, MD, PhD²², Massimo Offidani²³, Michele Cavo^10* and Mario Boccadoro²⁴

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Department of Hematology, Ankara University, Ankara, Turkey
³HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
⁴University of Athens School of Medicine, KIFISIA, Greece
⁵IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
⁶Wilhelminenspital, Vienna, Austria
⁷Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
⁸Medical Oncology, Luzerner Kantonsspital, Luzern, Switzerland
⁹University Hospital Ostrava, Ostrava, Czech Republic
¹⁰Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Experimental Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy
¹¹Myeloma Unit, Division of Hematology, University of Torino, A.O.U. S. Giovanni Battista, Torino, IT-TO, Italy
¹²Hematology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Milan, Italy
¹³Ospedale San Camillo Forlanini, Roma, ITA
¹⁴Department of Hematology, Transfusion Medicine and Biotechnology, "Santo Spirito" Civic Hospital, Pescara, Italy
¹⁵Department of Hematology, South Älvsborg Hospital, Boras, Sweden
¹⁶GIMEMA, European Myeloma Network, Italy
¹⁷Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
¹⁸Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
¹⁹Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
²⁰Instituto Português de Oncologia, Lisbon, Portugal
²¹Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
²²Oslo Myeloma Center/Department of Hematology, OSLO Univeristy Hospital, Oslo, Norway
²³GIMEMA, European Myeloma Network, Ancona, Italy
²⁴Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy

Thierry Facon, MD^1*, Christopher P. Venner^2*, Nizar Bahlis, MD³, Fritz Offner, MD, PhD⁴, Darrell J White, MD⁵, Lotfi Benboubker, MD^6*, Sophie Rigaudeau, MD^7*, Philippe Rodon, MD⁸, Sung-Soo Yoon, MD, PhD⁹, Kenshi Suzuki, MD, PhD¹⁰, Hirohiko Shibayama, MD, PhD¹¹, Xiaoquan Zhang, MD^12*, Godwin Yung^12*, Robert M. Rifkin, MD¹³, Philippe Moreau^14*, Sagar Lonial, MD¹⁵, Shaji K. Kumar, MD¹⁶, Paul G. Richardson, MD¹⁷ and S. Vincent Rajkumar, MD¹⁸

¹Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, Lille, France
²Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
³Division of Hematology and Oncology, Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
⁴Hematology, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium
⁵QEII Health Sciences Center and Dalhousie University, Halifax, NS, Canada
⁶Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France
⁷Department of Clinical Hematology, Centre Hospitalier Versailles, Le Chesnay, France
⁸Unite d'Hematologie et d'Oncologie, Centre Hospitalier Périgueux, Périgueux, France
⁹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
¹⁰Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
¹¹Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
¹²Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
¹³Rocky Mountain Cancer Center, Denver, CO
¹⁴Department of Hematology, University Hospital of Nantes, Nantes, France
¹⁵Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
¹⁶Division of Hematology, Mayo Clinic, Rochester, MN
¹⁷Dana-Farber Cancer Institute, Boston, MA
¹⁸Mayo Clinic Rochester, Division of Hematology, Rochester, MN

Raymond L. Comenzo, MD¹, Efstathios Kastritis, MD^2*, Giovanni Palladini, MD, PhD³, Monique C. Minnema⁴, Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM⁵, Arnaud Jaccard, MD, PhD^6*, Vaishali Sanchorawala, MD⁷, Hans C. Lee, MD⁸, Simon D. Gibbs, FRACP, FRCPA, MBBS^9*, Peter Mollee, FRACP, MBBS, MSc, FRCPA¹⁰, Christopher P. Venner, MD¹¹, Jin Lu¹², Stefan Schönland, MD^13*, Moshe Gatt, MD¹⁴, Kenshi Suzuki, MD, PhD¹⁵, Kihyun Kim, MD, PhD¹⁶, M. Teresa Cibeira, MD, PhD^17*, Meral Beksac, MD¹⁸, Edward Libby, MD¹⁹, Jason Valent, MD²⁰, Vania T. M. Hungria, MD, PhD²¹, Sandy W. Wong, MD²², Michael Rosenzweig, MD²³, Naresh Bumma, MD²⁴, Dominique Chauveau, MD, PhD^25*, Meletios A Dimopoulos²⁶, NamPhuong Tran, MD^27*, Xiang Qin, MD, PhD^28*, Sandra Y. Vasey, MSc^28*, Brenda Tromp, MSc²⁹, Brendan M. Weiss, MD^28*, Jessica Vermeulen, MD, PhD³⁰ and Giampaolo Merlini, MD³¹

¹Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
²Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece
³Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy
⁴Department of Hematology, UMC Utrecht, Utrecht, Netherlands
⁵University College London, London, United Kingdom
⁶Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France
⁷Amyloidosis Center, Boston University School of Medicine, Boston, MA
⁸Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁹The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia
¹⁰Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
¹¹Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
¹²Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China
¹³Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
¹⁴Department of Hematology, Hadassah-Hebrew University Medical Center-, Jerusalem, Israel
¹⁵Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan
¹⁶Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
¹⁷Hospital Clinic of Barcelona, Barcelona, Spain
¹⁸Cebeci Yerleskesi Dikimevi, Ankara, Turkey
¹⁹Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
²⁰Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²¹São Germano Clinic, São Paulo, Brazil
²²Tufts Medical Center, San Francisco, CA
²³Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
²⁴Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
²⁵CHU de Toulouse-Hôpital Rangueil, Toulouse, France
²⁶University of Athens School of Medicine, KIFISIA, Greece
²⁷Janssen Research & Development, LLC, Los Angeles, CA
²⁸Janssen Research & Development, LLC, Spring House, PA
²⁹Janssen Research & Development, LLC, Leiden, Netherlands
³⁰Janssen Research & Development, LLC, Leiden, CB, Netherlands
³¹Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy

Giovanni Palladini, MD, PhD¹, Stefan Schönland, MD^2*, Giampaolo Merlini, MD¹, Paolo Milani, MD, PhD¹, Arnaud Jaccard, MD, PhD^3*, Frank Bridoux, MD, PhD^4*, Wilfried Roeloffzen, MD, PhD^5*, M. Teresa Cibeira, MD, PhD^6*, Hermine Agis, MD⁷, Monique C. Minnema, MD, PhD⁸, Rui Bergantim, MD^9*, Roman Hajek, MD, PhD¹⁰, Cristina João, MD, PhD, MSc^11*, Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM¹², Pieter Sonneveld, MD, PhD¹³ and Efstathios Kastritis, MD^14*

¹Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
²Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
³National Amyloidosis Center and Hematology Unit, CHU Limoges, Limoges, France
⁴Nephrology Unit, CHU Poitiers, Poitiers, France
⁵Amyloidosis Centre of Expertise Department of Internal Medicine, Faculty of Medical Sciences,, University Medical Center Groningen, Groningen, Netherlands
⁶Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Spain
⁷Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
⁸Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
⁹Department of Hematology, Hospital São João, Porto, Portugal
¹⁰Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
¹¹Hematology Department, Champalimaud Centre for the Unknown, Lisbon, Portugal
¹²National Amyloidosis Centre, University College London, London, United Kingdom
¹³Erasmus MC Cancer Institute, Rotterdam, Netherlands
¹⁴Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece